Abbott Laboratories and Intuitive Surgical both reported strong fiscal second quarter 2026 results, with Abbott beating estimates and raising its annual profit forecast while Intuitive Surgical also topped consensus on revenue and earnings. Abbott's sales rose 13% on a reported basis and 4.8% on a comparable basis, driven by a 42% jump in diagnostics revenue to $3.09 billion, while Intuitive Surgical's revenue grew 19% to $2.89 billion with adjusted EPS of $2.80 exceeding expectations by $0.30. Abbott reaffirmed its full-year comparable sales growth guidance of 6.5% to 7.5%, while Intuitive Surgical kept its 2026 da Vinci procedure growth outlook at 13.5% to 15.5% and warned that tariffs could materially affect margins. Hedge fund ownership data showed Abbott's count rising from 71 to 73 and Intuitive Surgical's falling from 109 to 103 between the two quarters.
Abbott LaboratoriesAbbott beat estimates and raised annual profit forecast, with strong diagnostics revenue growth.
Intuitive Surgical IncIntuitive Surgical topped revenue and earnings consensus, with strong procedure growth outlook.
